Omeprazole (English Wikipedia)

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 445. ISBN 978-3-527-60749-5. Archived from the original on 3 August 2020. Retrieved 29 June 2020.

canada.ca (Global: 1,114^th place; English: 605^th place)

"Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 1 April 2024.

chemsrc.com (Global: low place; English: low place)

"Omeprazole MSDS". Archived from the original on 19 April 2017. Retrieved 21 October 2018.

clincalc.com (Global: 5,833^rd place; English: 4,432^nd place)

"The Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
"Omeprazole Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 12 August 2025.

cms.gov (Global: low place; English: low place)

"Proton Pump Inhibitor: Use in Adults" (PDF). CMS Medicaid Integrity Program. Archived from the original (PDF) on 12 December 2013. Retrieved 21 October 2018.

doi.org (Global: 2^nd place; English: 2^nd place)

Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcão A, et al. (2005). "Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions". Clinical Drug Investigation. 25 (6): 391–399. doi:10.2165/00044011-200525060-00004. PMID 17532679. S2CID 22082780. Archived from the original on 13 March 2013. Retrieved 21 October 2018.
Cheng E (July 2013). "Proton pump inhibitors for eosinophilic oesophagitis". Current Opinion in Gastroenterology. 29 (4): 416–420. doi:10.1097/MOG.0b013e32835fb50e. PMC 4118554. PMID 23449027.
Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F (October 2007). "Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication". Annals of Internal Medicine. 147 (8): 553–562. doi:10.7326/0003-4819-147-8-200710160-00008. PMID 17938394. S2CID 11644009.
Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. (June 2007). "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report". Gut. 56 (6): 772–781. doi:10.1136/gut.2006.101634. PMC 1954853. PMID 17170018.
McTavish D, Buckley MM, Heel RC (July 1991). "Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders". Drugs. 42 (1): 138–170. doi:10.2165/00003495-199142010-00008. PMID 1718683.
Abou Chakra CN, Pepin J, Sirard S, Valiquette L (June 2014). "Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review". PLOS ONE. 9 (6) e98400. Bibcode:2014PLoSO...998400A. doi:10.1371/journal.pone.0098400. PMC 4045753. PMID 24897375.
Yang YX, Lewis JD, Epstein S, Metz DC (December 2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA. 296 (24): 2947–2953. doi:10.1001/jama.296.24.2947. PMID 17190895.
Yu EW, Bauer SR, Bain PA, Bauer DC (June 2011). "Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies". The American Journal of Medicine. 124 (6): 519–526. doi:10.1016/j.amjmed.2011.01.007. PMC 3101476. PMID 21605729.
Hess MW, Hoenderop JG, Bindels RJ, Drenth JP (September 2012). "Systematic review: hypomagnesaemia induced by proton pump inhibition". Alimentary Pharmacology & Therapeutics. 36 (5): 405–413. doi:10.1111/j.1365-2036.2012.05201.x. PMID 22762246. S2CID 9073390.
Neal K, Logan R (July 2001). "Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors". Alimentary Pharmacology & Therapeutics. 15 (7): 1085–1086. doi:10.1046/j.1365-2036.2001.0994a.x. PMID 11421886. S2CID 39455836.
Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H (August 2011). "Association between proton pump inhibitor use and anemia: a retrospective cohort study". Digestive Diseases and Sciences. 56 (8): 2349–2353. doi:10.1007/s10620-011-1589-y. PMID 21318590. S2CID 33574008.
McColl KE (March 2009). "Effect of proton pump inhibitors on vitamins and iron". The American Journal of Gastroenterology. 104 (Suppl 2): S5–S9. doi:10.1038/ajg.2009.45. PMID 19262546. S2CID 31455416.
Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC (December 2007). "Proton pump inhibitor-induced acute interstitial nephritis". British Journal of Clinical Pharmacology. 64 (6): 819–823. doi:10.1111/j.1365-2125.2007.02927.x. PMC 2198775. PMID 17635502.
Corleto VD, Festa S, Di Giulio E, Annibale B (February 2014). "Proton pump inhibitor therapy and potential long-term harm". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (1): 3–8. doi:10.1097/med.0000000000000031. hdl:11573/618643. PMID 24310148. S2CID 205791135.
Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, et al. (July 2017). "Proton pump inhibitors: Risks of long-term use". Journal of Gastroenterology and Hepatology. 32 (7): 1295–1302. doi:10.1111/jgh.13737. PMID 28092694.
Pasternak B, Hviid A (November 2010). "Use of proton-pump inhibitors in early pregnancy and the risk of birth defects". The New England Journal of Medicine. 363 (22): 2114–2123. doi:10.1056/NEJMoa1002689. PMID 21105793. S2CID 10954538.
Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. (July 2012). "Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs". BMJ. 345 e4388. doi:10.1136/bmj.e4388. PMC 3392956. PMID 22782731.
Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW (April 2013). "Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review". Heart. 99 (8): 520–527. doi:10.1136/heartjnl-2012-302371. PMID 22851683. S2CID 23689175.
Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N (July 2013). "Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions". Drug Metabolism and Disposition. 41 (7): 1414–1424. doi:10.1124/dmd.113.051722. PMC 3684819. PMID 23620487.
Lau WC, Gurbel PA (March 2009). "The drug-drug interaction between proton pump inhibitors and clopidogrel". CMAJ. 180 (7): 699–700. doi:10.1503/cmaj.090251. PMC 2659824. PMID 19332744.
Norgard NB, Mathews KD, Wall GC (July 2009). "Drug-drug interaction between clopidogrel and the proton pump inhibitors". The Annals of Pharmacotherapy. 43 (7): 1266–1274. doi:10.1345/aph.1M051. PMID 19470853. S2CID 13227312.
Daly AK, King BP (May 2003). "Pharmacogenetics of oral anticoagulants". Pharmacogenetics. 13 (5): 247–252. doi:10.1097/00008571-200305000-00002. PMID 12724615.
Stedman CA, Barclay ML (August 2000). "Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors". Alimentary Pharmacology & Therapeutics. 14 (8): 963–978. doi:10.1046/j.1365-2036.2000.00788.x. PMID 10930890. S2CID 45337685.
Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (December 2001). "Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein". Naunyn-Schmiedeberg's Archives of Pharmacology. 364 (6): 551–557. doi:10.1007/s00210-001-0489-7. PMID 11770010. S2CID 19990184.
Izzo AA, Ernst E (2009). "Interactions between herbal medicines and prescribed drugs: an updated systematic review". Drugs. 69 (13): 1777–1798. doi:10.2165/11317010-000000000-00000. PMID 19719333. S2CID 25720882.
Howden CW (January 1991). "Clinical pharmacology of omeprazole". Clinical Pharmacokinetics. 20 (1): 38–49. doi:10.2165/00003088-199120010-00003. PMID 2029801. S2CID 25855436.
Cederberg C, Andersson T, Skånberg I (January 1989). "Omeprazole: pharmacokinetics and metabolism in man". Scandinavian Journal of Gastroenterology. Supplement. 166 (sup166): 33–40. doi:10.3109/00365528909091241. PMID 2690330.
Clissold SP, Campoli-Richards DM (July 1986). "Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome". Drugs. 32 (1): 15–47. doi:10.2165/00003495-198632010-00002. PMID 3527658.
Huttunen KM, Raunio H, Rautio J (September 2011). "Prodrugs--from serendipity to rational design". Pharmacological Reviews. 63 (3): 750–771. doi:10.1124/pr.110.003459. PMID 21737530.
Roche VF (October 2006). "The chemically elegant proton pump inhibitors". American Journal of Pharmaceutical Education. 70 (5): 101. doi:10.5688/aj7005101. PMC 1637016. PMID 17149430.
Shiohira H, Yasui-Furukori N, Yamada S, Tateishi T, Akamine Y, Uno T (August 2012). "Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes". Pharmaceutical Research. 29 (8): 2310–2316. doi:10.1007/s11095-012-0757-x. PMID 22549736.
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (June 2005). "Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies". Drug Metabolism and Pharmacokinetics. 20 (3): 153–167. doi:10.2133/dmpk.20.153. PMID 15988117. S2CID 19090952.
Katz PO, Gerson LB, Vela MF (March 2013). "Guidelines for the diagnosis and management of gastroesophageal reflux disease". The American Journal of Gastroenterology. 108 (3): 308–28, quiz 329. doi:10.1038/ajg.2012.444. PMID 23419381. S2CID 8198975.
Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand SE, et al. (March 1981). "Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase". Nature. 290 (5802): 159–161. Bibcode:1981Natur.290..159F. doi:10.1038/290159a0. PMID 6259537. S2CID 4368190.

drugbank.ca (Global: 5,595^th place; English: low place)

"Omeprazole". www.drugbank.ca. Archived from the original on 30 January 2019. Retrieved 29 January 2019.

drugs.com (Global: 529^th place; English: 550^th place)

"Omeprazole". The American Society of Health-System Pharmacists. Archived from the original on 19 February 2011. Retrieved 21 October 2018.
"Omeprazole international". Drugs.com. 3 February 2020. Archived from the original on 28 February 2020. Retrieved 27 February 2020.
"Omeprazole Use During Pregnancy". Drugs.com. 11 April 2019. Archived from the original on 15 February 2020. Retrieved 15 February 2020.

europa.eu (Global: 62^nd place; English: 100^th place)

ec.europa.eu

"Omeprazole TriviumVet PI". Union Register of medicinal products. 3 April 2025. Retrieved 3 May 2025.

ema.europa.eu

"Omeprazole TriviumVet EPAR". European Medicines Agency (EMA). 12 February 2025. Retrieved 16 February 2025.

fda.gov (Global: 470^th place; English: 329^th place)

fda.gov

"Questions and Answers on Prilosec OTC (omeprazole)". U.S. Food and Drug Administration (FDA). 3 November 2018. Archived from the original on 28 August 2021. Retrieved 2 March 2020.
Research Cf (3 November 2018). "Questions and Answers on Prilosec OTC (omeprazole)". FDA.
Research Cf (3 November 2018). "Prilosec OTC (omeprazole) Information". FDA.

accessdata.fda.gov

"Product Details for NDA 019810". U.S. Food and Drug Administration (FDA). 5 October 1995. Retrieved 9 July 2025.
"Drug Approval Package: Prilosec (Omeprazole Magnesium) NDA #021229". U.S. Food and Drug Administration (FDA). Archived from the original on 24 January 2022. Retrieved 6 October 2022.

hdl.handle.net (Global: 66^th place; English: 34^th place)

The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Corleto VD, Festa S, Di Giulio E, Annibale B (February 2014). "Proton pump inhibitor therapy and potential long-term harm". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (1): 3–8. doi:10.1097/med.0000000000000031. hdl:11573/618643. PMID 24310148. S2CID 205791135.

lifesciencesweden.se (Global: low place; English: low place)

Lagercrantz S (29 November 2022). "The stomach medication that became the biggest blockbuster of the 1990s". Life Science Sweden. Retrieved 9 July 2025.

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

"Omeprazole 40 mg Powder for Solution for Infusion". EMC. 10 February 2016. Archived from the original on 7 April 2016. Retrieved 21 October 2018.

medscape.com (Global: 1,078^th place; English: 916^th place)

medscape.com

Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcão A, et al. (2005). "Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions". Clinical Drug Investigation. 25 (6): 391–399. doi:10.2165/00044011-200525060-00004. PMID 17532679. S2CID 22082780. Archived from the original on 13 March 2013. Retrieved 21 October 2018.

emedicine.medscape.com

Selective Serotonin Reuptake Inhibitors and CYP2D6 at eMedicine

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcão A, et al. (2005). "Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions". Clinical Drug Investigation. 25 (6): 391–399. doi:10.2165/00044011-200525060-00004. PMID 17532679. S2CID 22082780. Archived from the original on 13 March 2013. Retrieved 21 October 2018.
Cheng E (July 2013). "Proton pump inhibitors for eosinophilic oesophagitis". Current Opinion in Gastroenterology. 29 (4): 416–420. doi:10.1097/MOG.0b013e32835fb50e. PMC 4118554. PMID 23449027.
Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F (October 2007). "Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication". Annals of Internal Medicine. 147 (8): 553–562. doi:10.7326/0003-4819-147-8-200710160-00008. PMID 17938394. S2CID 11644009.
Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. (June 2007). "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report". Gut. 56 (6): 772–781. doi:10.1136/gut.2006.101634. PMC 1954853. PMID 17170018.
McTavish D, Buckley MM, Heel RC (July 1991). "Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders". Drugs. 42 (1): 138–170. doi:10.2165/00003495-199142010-00008. PMID 1718683.
Abou Chakra CN, Pepin J, Sirard S, Valiquette L (June 2014). "Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review". PLOS ONE. 9 (6) e98400. Bibcode:2014PLoSO...998400A. doi:10.1371/journal.pone.0098400. PMC 4045753. PMID 24897375.
Yang YX, Lewis JD, Epstein S, Metz DC (December 2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA. 296 (24): 2947–2953. doi:10.1001/jama.296.24.2947. PMID 17190895.
Yu EW, Bauer SR, Bain PA, Bauer DC (June 2011). "Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies". The American Journal of Medicine. 124 (6): 519–526. doi:10.1016/j.amjmed.2011.01.007. PMC 3101476. PMID 21605729.
Hess MW, Hoenderop JG, Bindels RJ, Drenth JP (September 2012). "Systematic review: hypomagnesaemia induced by proton pump inhibition". Alimentary Pharmacology & Therapeutics. 36 (5): 405–413. doi:10.1111/j.1365-2036.2012.05201.x. PMID 22762246. S2CID 9073390.
Neal K, Logan R (July 2001). "Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors". Alimentary Pharmacology & Therapeutics. 15 (7): 1085–1086. doi:10.1046/j.1365-2036.2001.0994a.x. PMID 11421886. S2CID 39455836.
Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H (August 2011). "Association between proton pump inhibitor use and anemia: a retrospective cohort study". Digestive Diseases and Sciences. 56 (8): 2349–2353. doi:10.1007/s10620-011-1589-y. PMID 21318590. S2CID 33574008.
McColl KE (March 2009). "Effect of proton pump inhibitors on vitamins and iron". The American Journal of Gastroenterology. 104 (Suppl 2): S5–S9. doi:10.1038/ajg.2009.45. PMID 19262546. S2CID 31455416.
Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC (December 2007). "Proton pump inhibitor-induced acute interstitial nephritis". British Journal of Clinical Pharmacology. 64 (6): 819–823. doi:10.1111/j.1365-2125.2007.02927.x. PMC 2198775. PMID 17635502.
Corleto VD, Festa S, Di Giulio E, Annibale B (February 2014). "Proton pump inhibitor therapy and potential long-term harm". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (1): 3–8. doi:10.1097/med.0000000000000031. hdl:11573/618643. PMID 24310148. S2CID 205791135.
Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, et al. (July 2017). "Proton pump inhibitors: Risks of long-term use". Journal of Gastroenterology and Hepatology. 32 (7): 1295–1302. doi:10.1111/jgh.13737. PMID 28092694.
Pasternak B, Hviid A (November 2010). "Use of proton-pump inhibitors in early pregnancy and the risk of birth defects". The New England Journal of Medicine. 363 (22): 2114–2123. doi:10.1056/NEJMoa1002689. PMID 21105793. S2CID 10954538.
Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. (July 2012). "Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs". BMJ. 345 e4388. doi:10.1136/bmj.e4388. PMC 3392956. PMID 22782731.
Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW (April 2013). "Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review". Heart. 99 (8): 520–527. doi:10.1136/heartjnl-2012-302371. PMID 22851683. S2CID 23689175.
Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N (July 2013). "Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions". Drug Metabolism and Disposition. 41 (7): 1414–1424. doi:10.1124/dmd.113.051722. PMC 3684819. PMID 23620487.
Lau WC, Gurbel PA (March 2009). "The drug-drug interaction between proton pump inhibitors and clopidogrel". CMAJ. 180 (7): 699–700. doi:10.1503/cmaj.090251. PMC 2659824. PMID 19332744.
Norgard NB, Mathews KD, Wall GC (July 2009). "Drug-drug interaction between clopidogrel and the proton pump inhibitors". The Annals of Pharmacotherapy. 43 (7): 1266–1274. doi:10.1345/aph.1M051. PMID 19470853. S2CID 13227312.
Daly AK, King BP (May 2003). "Pharmacogenetics of oral anticoagulants". Pharmacogenetics. 13 (5): 247–252. doi:10.1097/00008571-200305000-00002. PMID 12724615.
Stedman CA, Barclay ML (August 2000). "Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors". Alimentary Pharmacology & Therapeutics. 14 (8): 963–978. doi:10.1046/j.1365-2036.2000.00788.x. PMID 10930890. S2CID 45337685.
Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (December 2001). "Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein". Naunyn-Schmiedeberg's Archives of Pharmacology. 364 (6): 551–557. doi:10.1007/s00210-001-0489-7. PMID 11770010. S2CID 19990184.
Izzo AA, Ernst E (2009). "Interactions between herbal medicines and prescribed drugs: an updated systematic review". Drugs. 69 (13): 1777–1798. doi:10.2165/11317010-000000000-00000. PMID 19719333. S2CID 25720882.
Howden CW (January 1991). "Clinical pharmacology of omeprazole". Clinical Pharmacokinetics. 20 (1): 38–49. doi:10.2165/00003088-199120010-00003. PMID 2029801. S2CID 25855436.
Cederberg C, Andersson T, Skånberg I (January 1989). "Omeprazole: pharmacokinetics and metabolism in man". Scandinavian Journal of Gastroenterology. Supplement. 166 (sup166): 33–40. doi:10.3109/00365528909091241. PMID 2690330.
Clissold SP, Campoli-Richards DM (July 1986). "Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome". Drugs. 32 (1): 15–47. doi:10.2165/00003495-198632010-00002. PMID 3527658.
Huttunen KM, Raunio H, Rautio J (September 2011). "Prodrugs--from serendipity to rational design". Pharmacological Reviews. 63 (3): 750–771. doi:10.1124/pr.110.003459. PMID 21737530.
Roche VF (October 2006). "The chemically elegant proton pump inhibitors". American Journal of Pharmaceutical Education. 70 (5): 101. doi:10.5688/aj7005101. PMC 1637016. PMID 17149430.
Shiohira H, Yasui-Furukori N, Yamada S, Tateishi T, Akamine Y, Uno T (August 2012). "Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes". Pharmaceutical Research. 29 (8): 2310–2316. doi:10.1007/s11095-012-0757-x. PMID 22549736.
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (June 2005). "Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies". Drug Metabolism and Pharmacokinetics. 20 (3): 153–167. doi:10.2133/dmpk.20.153. PMID 15988117. S2CID 19090952.
Katz PO, Gerson LB, Vela MF (March 2013). "Guidelines for the diagnosis and management of gastroesophageal reflux disease". The American Journal of Gastroenterology. 108 (3): 308–28, quiz 329. doi:10.1038/ajg.2012.444. PMID 23419381. S2CID 8198975.
Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand SE, et al. (March 1981). "Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase". Nature. 290 (5802): 159–161. Bibcode:1981Natur.290..159F. doi:10.1038/290159a0. PMID 6259537. S2CID 4368190.
Farley D (July–August 1995). "Making it easier to read prescriptions". FDA Consumer. 29 (6): 25–27. PMID 10143448. Archived from the original on 15 March 2012. Retrieved 26 January 2011.

ncbi.nlm.nih.gov

Cheng E (July 2013). "Proton pump inhibitors for eosinophilic oesophagitis". Current Opinion in Gastroenterology. 29 (4): 416–420. doi:10.1097/MOG.0b013e32835fb50e. PMC 4118554. PMID 23449027.
Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. (June 2007). "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report". Gut. 56 (6): 772–781. doi:10.1136/gut.2006.101634. PMC 1954853. PMID 17170018.
Abou Chakra CN, Pepin J, Sirard S, Valiquette L (June 2014). "Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review". PLOS ONE. 9 (6) e98400. Bibcode:2014PLoSO...998400A. doi:10.1371/journal.pone.0098400. PMC 4045753. PMID 24897375.
Yu EW, Bauer SR, Bain PA, Bauer DC (June 2011). "Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies". The American Journal of Medicine. 124 (6): 519–526. doi:10.1016/j.amjmed.2011.01.007. PMC 3101476. PMID 21605729.
Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC (December 2007). "Proton pump inhibitor-induced acute interstitial nephritis". British Journal of Clinical Pharmacology. 64 (6): 819–823. doi:10.1111/j.1365-2125.2007.02927.x. PMC 2198775. PMID 17635502.
Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. (July 2012). "Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs". BMJ. 345 e4388. doi:10.1136/bmj.e4388. PMC 3392956. PMID 22782731.
Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N (July 2013). "Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions". Drug Metabolism and Disposition. 41 (7): 1414–1424. doi:10.1124/dmd.113.051722. PMC 3684819. PMID 23620487.
Lau WC, Gurbel PA (March 2009). "The drug-drug interaction between proton pump inhibitors and clopidogrel". CMAJ. 180 (7): 699–700. doi:10.1503/cmaj.090251. PMC 2659824. PMID 19332744.
Roche VF (October 2006). "The chemically elegant proton pump inhibitors". American Journal of Pharmaceutical Education. 70 (5): 101. doi:10.5688/aj7005101. PMC 1637016. PMID 17149430.

dailymed.nlm.nih.gov

"Prilosec- omeprazole magnesium granule, delayed release". DailyMed. 19 March 2024. Retrieved 9 July 2025.
"Prilosec OTC- omeprazole magnesium tablet, delayed release". DailyMed. 10 October 2024. Retrieved 9 July 2025.
"Prilosec- omeprazole magnesium capsule, delayed release Prilosec- omeprazole magnesium granule, delayed release". DailyMed. 22 December 2016. Archived from the original on 27 December 2019. Retrieved 15 February 2020.
"Zegerid- omeprazole and sodium bicarbonate powder, for suspension Zegerid- omeprazole and sodium bicarbonate capsule". DailyMed. 4 March 2022. Retrieved 16 December 2022.
"Zegerid OTC- omeprazole and sodium bicarbonate capsule, gelatin coated". DailyMed. 5 December 2022. Retrieved 16 December 2022.
"Konvomep- omeprazole and sodium bicarbonate kit". DailyMed. 30 August 2022. Retrieved 21 January 2023.
"Nexium- esomeprazole magnesium capsule, delayed release; Nexium- esomeprazole magnesium granule, delayed release". DailyMed. 18 July 2023. Retrieved 9 July 2025.
"Omeprazole package insert". India: Dr. Reddy's Laboratories Limited. June 2013. Archived from the original on 19 April 2014.

reuters.com (Global: 38^th place; English: 30^th place)

"AstraZeneca to pay $425 mln to settle Nexium, Prilosec litigation in US". Reuters. 3 October 2023. Retrieved 3 October 2023.

scholar.google.com (Global: 1,418^th place; English: 768^th place)

"IN RE OMEPRAZOLE PATENT LITIGATION, Court of Appeals, Federal Circuit 2011". Google Scholar.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcão A, et al. (2005). "Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions". Clinical Drug Investigation. 25 (6): 391–399. doi:10.2165/00044011-200525060-00004. PMID 17532679. S2CID 22082780. Archived from the original on 13 March 2013. Retrieved 21 October 2018.
Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F (October 2007). "Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication". Annals of Internal Medicine. 147 (8): 553–562. doi:10.7326/0003-4819-147-8-200710160-00008. PMID 17938394. S2CID 11644009.
Hess MW, Hoenderop JG, Bindels RJ, Drenth JP (September 2012). "Systematic review: hypomagnesaemia induced by proton pump inhibition". Alimentary Pharmacology & Therapeutics. 36 (5): 405–413. doi:10.1111/j.1365-2036.2012.05201.x. PMID 22762246. S2CID 9073390.
Neal K, Logan R (July 2001). "Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors". Alimentary Pharmacology & Therapeutics. 15 (7): 1085–1086. doi:10.1046/j.1365-2036.2001.0994a.x. PMID 11421886. S2CID 39455836.
Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H (August 2011). "Association between proton pump inhibitor use and anemia: a retrospective cohort study". Digestive Diseases and Sciences. 56 (8): 2349–2353. doi:10.1007/s10620-011-1589-y. PMID 21318590. S2CID 33574008.
McColl KE (March 2009). "Effect of proton pump inhibitors on vitamins and iron". The American Journal of Gastroenterology. 104 (Suppl 2): S5–S9. doi:10.1038/ajg.2009.45. PMID 19262546. S2CID 31455416.
Corleto VD, Festa S, Di Giulio E, Annibale B (February 2014). "Proton pump inhibitor therapy and potential long-term harm". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (1): 3–8. doi:10.1097/med.0000000000000031. hdl:11573/618643. PMID 24310148. S2CID 205791135.
Pasternak B, Hviid A (November 2010). "Use of proton-pump inhibitors in early pregnancy and the risk of birth defects". The New England Journal of Medicine. 363 (22): 2114–2123. doi:10.1056/NEJMoa1002689. PMID 21105793. S2CID 10954538.
Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW (April 2013). "Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review". Heart. 99 (8): 520–527. doi:10.1136/heartjnl-2012-302371. PMID 22851683. S2CID 23689175.
Norgard NB, Mathews KD, Wall GC (July 2009). "Drug-drug interaction between clopidogrel and the proton pump inhibitors". The Annals of Pharmacotherapy. 43 (7): 1266–1274. doi:10.1345/aph.1M051. PMID 19470853. S2CID 13227312.
Stedman CA, Barclay ML (August 2000). "Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors". Alimentary Pharmacology & Therapeutics. 14 (8): 963–978. doi:10.1046/j.1365-2036.2000.00788.x. PMID 10930890. S2CID 45337685.
Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (December 2001). "Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein". Naunyn-Schmiedeberg's Archives of Pharmacology. 364 (6): 551–557. doi:10.1007/s00210-001-0489-7. PMID 11770010. S2CID 19990184.
Izzo AA, Ernst E (2009). "Interactions between herbal medicines and prescribed drugs: an updated systematic review". Drugs. 69 (13): 1777–1798. doi:10.2165/11317010-000000000-00000. PMID 19719333. S2CID 25720882.
Howden CW (January 1991). "Clinical pharmacology of omeprazole". Clinical Pharmacokinetics. 20 (1): 38–49. doi:10.2165/00003088-199120010-00003. PMID 2029801. S2CID 25855436.
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (June 2005). "Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies". Drug Metabolism and Pharmacokinetics. 20 (3): 153–167. doi:10.2133/dmpk.20.153. PMID 15988117. S2CID 19090952.
Katz PO, Gerson LB, Vela MF (March 2013). "Guidelines for the diagnosis and management of gastroesophageal reflux disease". The American Journal of Gastroenterology. 108 (3): 308–28, quiz 329. doi:10.1038/ajg.2012.444. PMID 23419381. S2CID 8198975.
Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand SE, et al. (March 1981). "Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase". Nature. 290 (5802): 159–161. Bibcode:1981Natur.290..159F. doi:10.1038/290159a0. PMID 6259537. S2CID 4368190.

thebody.com (Global: low place; English: low place)

Farley D (July–August 1995). "Making it easier to read prescriptions". FDA Consumer. 29 (6): 25–27. PMID 10143448. Archived from the original on 15 March 2012. Retrieved 26 January 2011.

thepharmaletter.com (Global: low place; English: low place)

"AstraZeneca/P&G's Prilosec OTC cleared by FDA for frequent heartburn". www.thepharmaletter.com. Retrieved 25 July 2025.

ubc.ca (Global: 1,820^th place; English: 998^th place)

ti.ubc.ca

"[99] Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative". 28 June 2016. Archived from the original on 30 October 2020. Retrieved 14 July 2016.

umn.edu (Global: 1,293^rd place; English: 776^th place)

d.umn.edu

Fitzakerley J. "2014 Treatments for Acid-Peptic Diseases". University of Minnesota Medical School Duluth. Archived from the original on 19 April 2014. Retrieved 21 October 2018.

uspharmacist.com (Global: low place; English: low place)

O'Neill LW, Culpepper BL, Galdo JA (December 2013). "Long-Term Consequences of Chronic Proton Pump Inhibitor Use". US Pharmacist. 38 (12): 38–42. Archived from the original on 21 January 2021. Retrieved 28 December 2020.

web.archive.org (Global: 1^st place; English: 1^st place)

"Omeprazole". The American Society of Health-System Pharmacists. Archived from the original on 19 February 2011. Retrieved 21 October 2018.
"Omeprazole international". Drugs.com. 3 February 2020. Archived from the original on 28 February 2020. Retrieved 27 February 2020.
"Omeprazole Use During Pregnancy". Drugs.com. 11 April 2019. Archived from the original on 15 February 2020. Retrieved 15 February 2020.
"Prilosec- omeprazole magnesium capsule, delayed release Prilosec- omeprazole magnesium granule, delayed release". DailyMed. 22 December 2016. Archived from the original on 27 December 2019. Retrieved 15 February 2020.
Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcão A, et al. (2005). "Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions". Clinical Drug Investigation. 25 (6): 391–399. doi:10.2165/00044011-200525060-00004. PMID 17532679. S2CID 22082780. Archived from the original on 13 March 2013. Retrieved 21 October 2018.
"Omeprazole MSDS". Archived from the original on 19 April 2017. Retrieved 21 October 2018.
"[99] Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative". 28 June 2016. Archived from the original on 30 October 2020. Retrieved 14 July 2016.
"Omeprazole 40 mg Powder for Solution for Infusion". EMC. 10 February 2016. Archived from the original on 7 April 2016. Retrieved 21 October 2018.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 445. ISBN 978-3-527-60749-5. Archived from the original on 3 August 2020. Retrieved 29 June 2020.
"The Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
"Questions and Answers on Prilosec OTC (omeprazole)". U.S. Food and Drug Administration (FDA). 3 November 2018. Archived from the original on 28 August 2021. Retrieved 2 March 2020.
"Drug Approval Package: Prilosec (Omeprazole Magnesium) NDA #021229". U.S. Food and Drug Administration (FDA). Archived from the original on 24 January 2022. Retrieved 6 October 2022.
O'Neill LW, Culpepper BL, Galdo JA (December 2013). "Long-Term Consequences of Chronic Proton Pump Inhibitor Use". US Pharmacist. 38 (12): 38–42. Archived from the original on 21 January 2021. Retrieved 28 December 2020.
Fitzakerley J. "2014 Treatments for Acid-Peptic Diseases". University of Minnesota Medical School Duluth. Archived from the original on 19 April 2014. Retrieved 21 October 2018.
"Proton Pump Inhibitor: Use in Adults" (PDF). CMS Medicaid Integrity Program. Archived from the original (PDF) on 12 December 2013. Retrieved 21 October 2018.
"Omeprazole". www.drugbank.ca. Archived from the original on 30 January 2019. Retrieved 29 January 2019.
"Omeprazole package insert". India: Dr. Reddy's Laboratories Limited. June 2013. Archived from the original on 19 April 2014.
"Trends in Drug Patenting - Case Studies: THE CASES: 5. OMEPRAZOLE". apps.who.int. Archived from the original on 2 October 2010. Retrieved 22 August 2019.
Farley D (July–August 1995). "Making it easier to read prescriptions". FDA Consumer. 29 (6): 25–27. PMID 10143448. Archived from the original on 15 March 2012. Retrieved 26 January 2011.
Harris G (6 June 2002). "Prilosec's Maker Switches Users to Nexium, Thwarting Generics". The Wall Street Journal. Archived from the original on 6 August 2017.

who.int (Global: 213^th place; English: 314^th place)

apps.who.int

"Trends in Drug Patenting - Case Studies: THE CASES: 5. OMEPRAZOLE". apps.who.int. Archived from the original on 2 October 2010. Retrieved 22 August 2019.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Vallerand AH, Sanoski CA, Deglin JH (2015). Davis's Drug Guide for Nurses (14th ed.). F.A. Davis Company. pp. 924–925. ISBN 978-0-8036-4085-6. OCLC 881473728.

wsj.com (Global: 94^th place; English: 66^th place)

Harris G (6 June 2002). "Prilosec's Maker Switches Users to Nexium, Thwarting Generics". The Wall Street Journal. Archived from the original on 6 August 2017.

youtube.com (Global: 13^th place; English: 14^th place)

Hummingbird Productions (19 July 2013). Prilosec OTC w/ Larry the Cable Guy. Retrieved 25 July 2025 – via YouTube.

Omeprazole (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

astrazeneca.com (Global: low place; English: low place)

books.google.com (Global: 3rd place; English: 3rd place)

canada.ca (Global: 1,114th place; English: 605th place)

chemsrc.com (Global: low place; English: low place)

clincalc.com (Global: 5,833rd place; English: 4,432nd place)

cms.gov (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

drugbank.ca (Global: 5,595th place; English: low place)

drugs.com (Global: 529th place; English: 550th place)

europa.eu (Global: 62nd place; English: 100th place)

ec.europa.eu

ema.europa.eu

fda.gov (Global: 470th place; English: 329th place)

fda.gov

accessdata.fda.gov

hdl.handle.net (Global: 66th place; English: 34th place)

lifesciencesweden.se (Global: low place; English: low place)

medicines.org.uk (Global: 4,892nd place; English: 3,451st place)

medscape.com (Global: 1,078th place; English: 916th place)

medscape.com

emedicine.medscape.com

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

reuters.com (Global: 38th place; English: 30th place)

scholar.google.com (Global: 1,418th place; English: 768th place)

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

thebody.com (Global: low place; English: low place)

thepharmaletter.com (Global: low place; English: low place)

ubc.ca (Global: 1,820th place; English: 998th place)

ti.ubc.ca

umn.edu (Global: 1,293rd place; English: 776th place)

d.umn.edu

uspharmacist.com (Global: low place; English: low place)

web.archive.org (Global: 1st place; English: 1st place)

who.int (Global: 213th place; English: 314th place)

apps.who.int

worldcat.org (Global: 4th place; English: 4th place)

search.worldcat.org

wsj.com (Global: 94th place; English: 66th place)

youtube.com (Global: 13th place; English: 14th place)

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

canada.ca (Global: 1,114^th place; English: 605^th place)

clincalc.com (Global: 5,833^rd place; English: 4,432^nd place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugbank.ca (Global: 5,595^th place; English: low place)

drugs.com (Global: 529^th place; English: 550^th place)

europa.eu (Global: 62^nd place; English: 100^th place)

fda.gov (Global: 470^th place; English: 329^th place)

hdl.handle.net (Global: 66^th place; English: 34^th place)

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

medscape.com (Global: 1,078^th place; English: 916^th place)

nih.gov (Global: 5^th place; English: 5^th place)

reuters.com (Global: 38^th place; English: 30^th place)

scholar.google.com (Global: 1,418^th place; English: 768^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

ubc.ca (Global: 1,820^th place; English: 998^th place)

umn.edu (Global: 1,293^rd place; English: 776^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

who.int (Global: 213^th place; English: 314^th place)

worldcat.org (Global: 4^th place; English: 4^th place)

wsj.com (Global: 94^th place; English: 66^th place)

youtube.com (Global: 13^th place; English: 14^th place)